Elevated ST2 Distinguishes Incidences of Pediatric Heart and Small Bowel Transplant Rejection

摘要: Elevated serum soluble (s) suppressor of tumorigenicity-2 is observed during cardiovascular and inflammatory bowel diseases. To ascertain whether modulated ST2 levels signify heart (HTx) or small transplant (SBTx) rejection, we quantified sST2 in serially obtained pediatric HTx (n = 41) SBTx recipient 18) sera. At times biopsy-diagnosed rejection (cellular and/or antibody-mediated), was elevated compared to rejection-free time points (1714 ± 329 vs. 546.5 141.6 pg/mL; p 0.0002). recipients also displayed increased incidences (7536 1561 2662 543.8 0.0347). Receiver operator characteristic (ROC) analysis showed that > 600 pg/mL could discriminate nonrejection (area under the curve [AUC] 0.724 0.053; 0.0003). ROC measures revealed a similar discriminative capacity (AUC 0.6921 0.0820; 0.0349). Quantitative evaluation both biopsies significantly allograft expression. Pathway Network Analysis biopsy data pinpointed dominant pathway by predicted tumor necrosis factor-α IL-1β as upstream activators. In total, our indicate alloimmune-associated pro-inflammatory cytokines increase rejection. They demonstrate routine quantification, potentially combined with other biomarkers, should be investigated further aid noninvasive diagnosis